<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-32881" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Metolazone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bond</surname>
            <given-names>Gretchen</given-names>
          </name>
          <aff>University Louisiana Monroe College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adnan</surname>
            <given-names>Ghufran</given-names>
          </name>
          <aff>Aga Khan University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dua</surname>
            <given-names>Anterpreet</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Karampal</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Crew</surname>
            <given-names>Cassie M.</given-names>
          </name>
          <aff>University of Louisiana Monroe</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gretchen Bond declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ghufran Adnan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anterpreet Dua declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karampal Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Cassie Crew declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-32881.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Metolazone is a cardiovascular agent, specifically a quinazoline diuretic related to the thiazide class. Metolazone works by inhibiting sodium transport across the epithelium of the renal tubules (mostly in the distal tubules), decreasing sodium reabsorption, and increasing sodium, chloride, and water excretion. The FDA has approved metolazone to treat salt and water retention, causing edema accompanying congestive heart failure or kidney disease. It is available in a generic formulation in the United States. It is used alone or with other diuretics in congestive heart failure, to treat hypertension, and in other conditions where diuresis provides a clinical benefit. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of metolazone, pertinent for interprofessional team members in treating patients with conditions where it is of clinical value.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of metolazone.</p></list-item><list-item><p>Review the various indications for using metolazone in patient care.</p></list-item><list-item><p>Summarize the adverse events associated with metolazone therapy.</p></list-item><list-item><p>Outline the contraindications to metolazone therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32881&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32881">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-32881.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Metolazone is a quinazoline sulphonamide diuretic related to the thiazide class. The Food and Drug&#x000a0;Administration (FDA) has approved metolazone to treat&#x000a0;salt and water retention, causing edema accompanying congestive heart failure or chronic kidney&#x000a0;disease. It is commonly used as adjuvant therapy and loop diuretics for treating severe CHF to produce diuresis in patients refractory to loop diuretics monotherapy.<xref ref-type="bibr" rid="article-32881.r1">[1]</xref>&#x000a0;The synergy of these diuretics may help overcome the resistance that&#x000a0;can develop with continued loop diuretic use.<xref ref-type="bibr" rid="article-32881.r2">[2]</xref>&#x000a0;Failure to decrease extracellular fluid volume despite using diuretics appropriately is termed &#x02018;diuretic resistance.&#x02019;&#x000a0; Diuretic resistance can be expressed as a fractional excretion of sodium (FENa) of &#x0003c;0.2% despite high dose&#x000a0;diuretics.&#x000a0;Metolazone is specifically used for diuretic resistance in the therapeutic management of edema and volume overload.<xref ref-type="bibr" rid="article-32881.r3">[3]</xref></p>
        <p>The drug&#x000a0;can be used to treat edema associated with nephrotic syndrome alone or in combination with spironolactone. Also, metolazone is indicated to treat hypertension alone or in combination&#x000a0;with other antihypertensive drugs of a different class.<xref ref-type="bibr" rid="article-32881.r4">[4]</xref>&#x000a0;According to&#x000a0;2022 AHA/ACC/HFSA guidelines, in&#x000a0;patients with congestive heart failure, the addition of metolazone to treatment&#x000a0;with a loop diuretic should be reserved&#x000a0;for patients who do not respond to moderate or&#x000a0;high-dose loop diuretics to minimize electrolyte&#x000a0;abnormalities.<xref ref-type="bibr" rid="article-32881.r5">[5]</xref></p>
      </sec>
      <sec id="article-32881.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Metolazone works by inhibiting sodium transport across the epithelium of the renal tubules (mostly in the distal tubules), decreasing sodium reabsorption, and increasing sodium, chloride, and water excretion. The shift in water and electrolytes results in hypovolemia, keeping the peripheral vascular resistance low and returning the cardiac output to normal. This production of diuresis resolves edema and contributes to the antihypertensive effect.&#x000a0;While metolazone is similar to thiazide diuretics in its mechanism of action, it does differ in its use in patients with impaired renal function. Thiazide diuretics decrease glomerular filtration rate (GFR) and are, therefore, less effective in patients with renal impairment. Because metolazone works primarily in the distal convoluted tubule rather than the proximal convoluted tubule, it has little effect on GFR. It can be used in patients with a reduced GFR.<xref ref-type="bibr" rid="article-32881.r6">[6]</xref>&#x000a0;</p>
        <p>Moreover, unlike loop diuretics, metolazone does not prompt renin secretion at the macula densa due to the stimulation of the renin-angiotensin-aldosterone system.&#x000a0;The use of thiazide-like diuretic (e.g., metolazone) in combination&#x000a0;with a loop diuretic interferes with compensatory distal&#x000a0;tubular sodium reabsorption, leading to&#x000a0;increased&#x000a0;natriuresis.<xref ref-type="bibr" rid="article-32881.r5">[5]</xref>&#x000a0;According to KDIGO (Kidney Disease Improving Global Outcomes) 2021 guidelines,&#x000a0; combining a loop diuretic with a thiazide-like diuretic (hydrochlorothiazide, metolazone) can be an effective oral regimen to overcome diuretic resistance by blocking sodium resorption at several sites within the nephron.<xref ref-type="bibr" rid="article-32881.r7">[7]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The data extrapolated from the recent study regarding the pharmacokinetics of metolazone is as follows.<xref ref-type="bibr" rid="article-32881.r8">[8]</xref></p>
        <p>Absorption: Oral Metolazone is rapidly absorbed after oral administration. Food delays the absorption of metolazone. The time to maximum plasma concentration is approximately 1.5 hours.&#x000a0;</p>
        <p>Distribution: Volume of distribution ranges from 108.7&#x000b1;&#x000a0;21.3 Liters to&#x000a0;126.3 &#x000b1;&#x000a0;53.4 Liters(Dose range 0.5 mg to 2 mg). Metolazone exhibits high plasma protein binding- PPB is 95%. <xref ref-type="bibr" rid="article-32881.r9">[9]</xref></p>
        <p>Metabolism:&#x000a0;Metolazone&#x000a0;undergoes&#x000a0;enterohepatic circulation. A study also indicates that metolazone affects&#x000a0;the hPXR-mediated expression of CYP3A4 and MDR1 in human hepatocytes and increases CYP3A4 activity in various cell lines.<xref ref-type="bibr" rid="article-32881.r10">[10]</xref></p>
        <p>Elimination:&#x000a0;The mean elimination half-life of metolazone is between&#x000a0;6 to 8 hours. Metolazone is primarily excreted in the urine.</p>
      </sec>
      <sec id="article-32881.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Metolazone is an oral agent, available in 2.5 mg, 5 mg, and 10 mg tablets. A dose of 5&#x000a0;to 20 mg once daily is recommended as the initial to treat edema associated with congestive heart failure or kidney disease. The dose should be titrated to the patient's response, then continued at the lowest dose needed to maintain diuresis. For the treatment of hypertension, 2.5-10 mg once daily is recommended initially, with titration to the response.<xref ref-type="bibr" rid="article-32881.r11">[11]</xref>&#x000a0;The safety and efficacy of specific pediatric dosing have not been established. However, one study suggests 0.2&#x000a0;to 0.4 mg/kg/day by mouth every 12&#x000a0;to 24 hours.<xref ref-type="bibr" rid="article-32881.r12">[12]</xref>&#x000a0;&#x000a0;</p>
        <p>Metolazone is recommended to be taken in the morning due to its prolonged absorption and duration of action.&#x000a0;According to guidelines, metolazone should be administered two to five hours before loop diuretic so that peak drug levels of metolazone are&#x000a0;attained with the loop diuretic administration and maximum&#x000a0;blockade of distal sodium reabsorption is accomplished.<xref ref-type="bibr" rid="article-32881.r7">[7]</xref></p>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p><bold>Patients with&#x000a0;Hepatic Impairment:</bold> No dose adjustment is required for patients with hepatic impairment</p>
        <p><bold>Patients with Renal Impairment:</bold> No dose adjustment is required for patients with renal impairment or with concurrent use of hemodialysis. Older patients are more likely to have decreased renal function; thus, care should be taken in dose selection, and renal function should be monitored.</p>
        <p><bold>Pregnancy Considerations:</bold> Metolazone is former FDA category B.&#x000a0; Metolazone crosses the placenta. Monitor for volume depletion to ensure adequate placental perfusion. The risk of exposure to the infant should be weighed against the benefit of treatment for the mother.<xref ref-type="bibr" rid="article-32881.r13">[13]</xref></p>
        <p><bold>Breastfeeding Considerations:&#x000a0;</bold>Metolazone is also excreted in breast milk, so the potential for adverse reactions in nursing infants exists.<xref ref-type="bibr" rid="article-32881.r13">[13]</xref>&#x000a0;Metolazone tablets are indicated in pregnancy when it is pathological. The risk of exposure to the infant should be weighed against the benefit of treatment for the mother. Also, Severe&#x000a0;diuresis with large doses of metolazone may decrease breast milk production. Other diuretics in low doses are preferred over metolazone.<xref ref-type="bibr" rid="article-32881.r14">[14]</xref></p>
      </sec>
      <sec id="article-32881.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Hyperuricemia is a common adverse effect due to competitive inhibition of uric acid secretion and a decrease in extracellular fluid from diuretic effects. Other fluid and electrolyte imbalances may occur, especially hyponatremia, hypokalemia, and hypomagnesemia. Any electrolyte imbalances must be corrected before starting treatment.<xref ref-type="bibr" rid="article-32881.r15">[15]</xref>&#x000a0;Metolazone may impair glucose tolerance, causing hyperglycemia and glycosuria. Diabetic patients should monitor their blood and urine glucose levels while on this therapy.<xref ref-type="bibr" rid="article-32881.r16">[16]</xref>&#x000a0;</p>
        <p>Diuretic therapy may be associated with increased serum cholesterol and triglycerides; however, long-term studies have found that serum cholesterol levels return to normal or below the baseline after approximately one year of therapy. These temporary effects do not significantly increase the risk of coronary heart disease.<xref ref-type="bibr" rid="article-32881.r17">[17]</xref>&#x000a0;</p>
        <p>The patient may experience orthostatic hypotension, which can be worsened by other antihypertensive agents, alcohol, or narcotic medications. A weak association has been made between diuretic use and falls in the elderly, so caution should be used in patients 60 years and older.<xref ref-type="bibr" rid="article-32881.r18">[18]</xref>&#x000a0;&#x000a0;Because metolazone exerts its main effect in the distal tubule of the nephron, a&#x000a0;change in renal function can be expected&#x000a0;and lead to occasional instances of&#x000a0;acute kidney injury. The likelihood of these events has not been established, and metolazone may be the only option indicated with reduced renal function.<xref ref-type="bibr" rid="article-32881.r19">[19]</xref>&#x000a0;&#x000a0;</p>
        <p>Other rare adverse effects include agranulocytosis, photosensitization, aplastic anemia, Stevens-Johnson syndrome, and toxic epidermal necrolysis.<xref ref-type="bibr" rid="article-32881.r20">[20]</xref> &#x000a0;</p>
        <p>In a study of&#x000a0;acute decompensated heart failure treatment metolazone with loop diuretics, metolazone therapy&#x000a0;was&#x000a0;associated with hypokalemia, hyponatremia, and deteriorating renal function in some patients.<xref ref-type="bibr" rid="article-32881.r19">[19]</xref></p>
        <p>The BRASH syndrome is the term used for (Bradycardia, Renal failure, AV blockade, Shock, and Hyperkalaemia) and has been associated with metolazone therapy.<xref ref-type="bibr" rid="article-32881.r21">[21]</xref></p>
        <p>Drug-induced cholestasis and hepatotoxicity have been reported.<xref ref-type="bibr" rid="article-32881.r9">[9]</xref><xref ref-type="bibr" rid="article-32881.r22">[22]</xref></p>
      </sec>
      <sec id="article-32881.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Different brands of metolazone are not therapeutically equivalent. FDA labeling recommended not to interchange formulations of metolazone.&#x000a0;</p>
        <p>Therapy is contraindicated in those with known metolazone hypersensitivity. Although this medication is a thiazide-like diuretic, cross-reactivity is rarely seen between metolazone and other diuretics.<xref ref-type="bibr" rid="article-32881.r23">[23]</xref>&#x000a0;However, there is limited evidence of cross-reactivity between sulfonamide agents and metolazone; nevertheless,&#x000a0;caution should&#x000a0;be used in those with a sulfonamide allergy because metolazone possesses&#x000a0;the chemical side chain.<xref ref-type="bibr" rid="article-32881.r24">[24]</xref>&#x000a0;Metolazone&#x000a0;should not be used in patients experiencing a hepatic coma or hepatic encephalopathy because electrolyte disturbances can occur and exacerbate these disease processes.<xref ref-type="bibr" rid="article-32881.r25">[25]</xref></p>
        <p>Anuric patients should have metolazone withheld. As the kidneys excrete metolazone, renal&#x000a0;impairment can cause a dangerous accumulation of the metolazone. Metalozone&#x000a0;is safe to use in mild to moderate renal impairment, unlike other thiazide diuretics, but extreme&#x000a0;caution should be used in those with severe renal impairment or anuria. Concurrent electrolyte&#x000a0;imbalance is a contraindication to metolazone therapy, as these should be corrected before initiating metolazone.<xref ref-type="bibr" rid="article-32881.r15">[15]</xref><xref ref-type="bibr" rid="article-32881.r19">[19]</xref>&#x000a0;</p>
        <p>Drug-Drug Interactions: Metolazone should be avoided in patients on lithium and digitalis as it can aggravate lithium and digitalis toxicity.<xref ref-type="bibr" rid="article-32881.r26">[26]</xref></p>
      </sec>
      <sec id="article-32881.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>To monitor the effectiveness of therapy in treating edema, the patient should show an increase in urine output and a decrease in total body weight.&#x000a0;In managing hypertension, a lowering in blood pressure should be seen within a few weeks of initiation of therapy. Current guidelines for high blood pressure treatment suggest assessing blood pressure monthly when starting&#x000a0;or adjusting therapy and every 3&#x000a0;to 6 months for patients at goal.<xref ref-type="bibr" rid="article-32881.r11">[11]</xref></p>
        <p>Additionally,&#x000a0;because of the adverse effects of metolazone, serum electrolytes should&#x000a0;be monitored at baseline and routinely while continuing therapy, including sodium, potassium, magnesium, and chloride.<xref ref-type="bibr" rid="article-32881.r15">[15]</xref><xref ref-type="bibr" rid="article-32881.r19">[19]</xref>&#x000a0;Although evidence is controversial&#x000a0;regarding hyperglycemia with metolazone, diabetic patients should monitor their serum glucose regularly while on this medication.<xref ref-type="bibr" rid="article-32881.r16">[16]</xref></p>
        <p>Failure to decrease extracellular fluid volume despite using diuretics appropriately is termed &#x02018;diuretic resistance.&#x02019;&#x000a0; Diuretic resistance can be expressed as a fractional sodium excretion (FE) of &#x0003c;0.2%.<xref ref-type="bibr" rid="article-32881.r3">[3]</xref></p>
        <p>Monitor the&#x000a0;health-related quality of life by&#x000a0;Kansas City Cardiomyopathy&#x000a0;Questionnaire&#x02013;12 (KCCQ-12).<xref ref-type="bibr" rid="article-32881.r27">[27]</xref></p>
      </sec>
      <sec id="article-32881.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>For diuretics in general,&#x000a0;toxic doses are not well established. Chronic use is the most common cause of toxicity, such as hypotension and increased hematocrit due to plasma volume depletion and syncope. Hypokalemia, hyponatremia and reduced renal function, and increased mortality have been reported with the use of metolazone.<xref ref-type="bibr" rid="article-32881.r19">[19]</xref>&#x000a0;Sodium levels&#x000a0;should be corrected according to serum glucose levels.&#x000a0;</p>
        <p>There is no antidote to metolazone. Supportive measures should be instituted as soon as possible to maintain hydration, electrolyte balance, respiration, and cardiovascular and renal function. Due to its high plasma protein binding, it is not removed by dialysis.<xref ref-type="bibr" rid="article-32881.r9">[9]</xref>&#x000a0;Call the United states poison control center (800-222-1222) for the latest information&#x000a0;regarding&#x000a0;the management of specific overdoses.<xref ref-type="bibr" rid="article-32881.r28">[28]</xref></p>
      </sec>
      <sec id="article-32881.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Congestive heart failure (CHF) patients can benefit from metolazone's diuretic effect. In one trial, adding metolazone to a loop diuretic (furosemide) in treating edema associated with CHF showed an increase in diuresis, urinary output, and weight loss compared to furosemide or metolazone alone.<xref ref-type="bibr" rid="article-32881.r29">[29]</xref>&#x000a0;Comparing metolazone to chlorothiazide in acutely decompensated heart failure patients with diuretic resistance, patients had an increase in 72-hour urine output and a shorter hospital stay when using metolazone.<xref ref-type="bibr" rid="article-32881.r30">[30]</xref>&#x000a0;[Level 3] Along with treating edema, low-dose metolazone&#x000a0;can significantly change systolic and diastolic blood pressure in treating hypertension.<xref ref-type="bibr" rid="article-32881.r31">[31]</xref>&#x000a0;[Level 1]&#x000a0;</p>
        <p>Effective treatment of edema associated with congestive heart failure and kidney disease requires the participation of every interprofessional healthcare team member. Metolazone is typically prescribed by clinicians (MDs, DOs, NPs, PAs) in patients with congestive heart failure with significant congestion and&#x000a0;resistance to loop diuretics. Usually, heart failure specialist consultation is required to manage volume overload in acute decompensated heart failure. Nephrologist consultation is necessary for patients with edema due to&#x000a0;kidney disease. Pharmacists should verify the dosing and check for potential drug interactions, reporting any concerns to the nursing staff or prescriber. Nursing should note any adverse events during metolazone therapy, monitor body weight and urine output, and reach out to the pharmacist if they have any questions. Both nursing and pharmacy have a significant responsibility in patient counseling.</p>
        <p>In acute decompensated heart failure, close communication and collaboration between different team members are vital to&#x000a0;optimize the outcomes related to metolazone therapy and minimize adverse drug reactions. According to&#x000a0;&#x000a0;2022 AHA/ACC/HFSA guidelines, patients should receive treatment from multidisciplinary teams to facilitate the implementation&#x000a0;of&#x000a0;Goal-directed medical therapy (GDMT); hence; an interprofessional team approach and collaboration between&#x000a0;cardiologists,&#x000a0;HF specialists, nurses, pharmacists, dieticians,&#x000a0;primary care&#x000a0;clinicians, social workers, primary care&#x000a0;clinicians, and additional specialists is crucial to optimize outcomes related to metolazone therapy with minimal adverse drug reactions.<xref ref-type="bibr" rid="article-32881.r5">[5]</xref>&#x000a0;[Level 1]</p>
      </sec>
      <sec id="article-32881.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32881&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32881">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/32881/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=32881">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-32881.s11">
        <title>References</title>
        <ref id="article-32881.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gustafsson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galatius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hildebrandt</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-6</page-range>
            <pub-id pub-id-type="pmid">16189620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palazzuoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruocco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Severino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gennari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pirrotta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stefanini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tramonte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Feola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mancone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fedele</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Effects of Metolazone Administration on Congestion, Diuretic Response and Renal Function in Patients with Advanced Heart Failure.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>17</day>
            <volume>10</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">34575318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Madanieh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alkan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dogar</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Kosmas</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Vittorio</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>A perspective on diuretic resistance in chronic congestive heart failure.</article-title>
            <source>Ther Adv Cardiovasc Dis</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>271</fpage>
            <page-range>271-278</page-range>
            <pub-id pub-id-type="pmid">28728476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Musini</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Nazer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bassett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>May</month>
            <day>29</day>
            <volume>2014</volume>
            <issue>5</issue>
            <fpage>CD003824</fpage>
            <pub-id pub-id-type="pmid">24869750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>145</volume>
            <issue>18</issue>
            <fpage>e895</fpage>
            <page-range>e895-e1032</page-range>
            <pub-id pub-id-type="pmid">35363499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paton</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1977</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-51</page-range>
            <pub-id pub-id-type="pmid">849998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group</collab>
            <article-title>KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.</article-title>
            <source>Kidney Int</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>100</volume>
            <issue>4S</issue>
            <fpage>S1</fpage>
            <page-range>S1-S276</page-range>
            <pub-id pub-id-type="pmid">34556256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic study of single- and multiple-dosing with metolazone tablets in healthy Chinese population.</article-title>
            <source>BMC Pharmacol Toxicol</source>
            <year>2017</year>
            <month>Nov</month>
            <day>16</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <pub-id pub-id-type="pmid">29145890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>K&#x000f6;ck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sedykh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tropsha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.</article-title>
            <source>J Pharm Sci</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>102</volume>
            <issue>9</issue>
            <fpage>3037</fpage>
            <page-range>3037-57</page-range>
            <pub-id pub-id-type="pmid">23653385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banerjee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Thiazide-like diuretic drug metolazone activates human pregnane X receptor to induce cytochrome 3A4 and multidrug-resistance protein 1.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2014</year>
            <month>Nov</month>
            <day>15</day>
            <volume>92</volume>
            <issue>2</issue>
            <fpage>389</fpage>
            <page-range>389-402</page-range>
            <pub-id pub-id-type="pmid">25181459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brook</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Rajagopalan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Am Soc Hypertens</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <pub-id pub-id-type="pmid">29396104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of metolazone and furosemide in children with furosemide-resistant edema.</article-title>
            <source>Pediatrics</source>
            <year>1984</year>
            <month>Nov</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>872</fpage>
            <page-range>872-5</page-range>
            <pub-id pub-id-type="pmid">6493882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <collab>American Academy of Pediatrics Committee on Drugs</collab>
            <article-title>Transfer of drugs and other chemicals into human milk.</article-title>
            <source>Pediatrics</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>108</volume>
            <issue>3</issue>
            <fpage>776</fpage>
            <page-range>776-89</page-range>
            <pub-id pub-id-type="pmid">11533352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Metolazone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shulenberger</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Devabhakthuni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ivaturi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>BN</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance.</article-title>
            <source>Pharmacotherapy</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>8</issue>
            <fpage>852</fpage>
            <page-range>852-60</page-range>
            <pub-id pub-id-type="pmid">27393709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper-DeHoff</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beitelshees</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Zineh</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gums</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Boerwinkle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.</article-title>
            <source>Hypertension</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-8</page-range>
            <pub-id pub-id-type="pmid">19917874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freis</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Critique of the clinical importance of diurectic-induced hypokalemia and elevated cholesterol level.</article-title>
            <source>Arch Intern Med</source>
            <year>1989</year>
            <month>Dec</month>
            <volume>149</volume>
            <issue>12</issue>
            <fpage>2640</fpage>
            <page-range>2640-8</page-range>
            <pub-id pub-id-type="pmid">2688584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leipzig</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cumming</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Tinetti</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-50</page-range>
            <pub-id pub-id-type="pmid">9920228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brisco-Bacik</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ter Maaten</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Houser</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Vedage</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Testani</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2018</year>
            <month>Sep</month>
            <day>18</day>
            <volume>7</volume>
            <issue>18</issue>
            <fpage>e009149</fpage>
            <pub-id pub-id-type="pmid">30371181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chauhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Charaniya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Metolazone Associated Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>FD01</fpage>
            <page-range>FD01-2</page-range>
            <pub-id pub-id-type="pmid">27134890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kemnic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hildebrandt</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>BRASH syndrome.</article-title>
            <source>BMJ Case Rep</source>
            <year>2020</year>
            <month>Feb</month>
            <day>23</day>
            <volume>13</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">32094236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Thiazide Diuretics</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>10</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">31643991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sullivan</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides.</article-title>
            <source>JAMA</source>
            <year>1991</year>
            <month>Jan</month>
            <day>02</day>
            <volume>265</volume>
            <issue>1</issue>
            <fpage>120</fpage>
            <page-range>120-1</page-range>
            <pub-id pub-id-type="pmid">1984112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Healy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Crownover</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical inquiries. Which diuretics are safe and effective for patients with a sulfa allergy?</article-title>
            <source>J Fam Pract</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>488</fpage>
            <page-range>488-90</page-range>
            <pub-id pub-id-type="pmid">17543262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hillenbrand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sherlock</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Use of metolazone in the treatment of ascites due to liver disease.</article-title>
            <source>Br Med J</source>
            <year>1971</year>
            <month>Oct</month>
            <day>30</day>
            <volume>4</volume>
            <issue>5782</issue>
            <fpage>266</fpage>
            <page-range>266-70</page-range>
            <pub-id pub-id-type="pmid">5123909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Diuretic-related side effects: development and treatment.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>532</fpage>
            <page-range>532-40</page-range>
            <pub-id pub-id-type="pmid">15365284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stubblefield</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Storrow</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Char</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Fermann</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hiestand</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindenfeld</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McNaughton</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Schrock</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Self</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department.</article-title>
            <source>Circ Cardiovasc Qual Outcomes</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>e007956</fpage>
            <pub-id pub-id-type="pmid">34555929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gahagan</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Hatlestad</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Delayed poisoning emergencies.</article-title>
            <source>Emerg Med Serv</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>80</fpage>
            <page-range>80-7</page-range>
            <pub-id pub-id-type="pmid">12942915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grosskopf</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rabinovitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Combination of furosemide and metolazone in the treatment of severe congestive heart failure.</article-title>
            <source>Isr J Med Sci</source>
            <year>1986</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>787</fpage>
            <page-range>787-90</page-range>
            <pub-id pub-id-type="pmid">3793436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moranville</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance.</article-title>
            <source>Cardiovasc Ther</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>42</fpage>
            <page-range>42-9</page-range>
            <pub-id pub-id-type="pmid">25712736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32881.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curry</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Janda</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>MacKay</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Nugent</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schnaper</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schoenberger</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical studies of a new, low-dose formulation of metolazone for the treatment of hypertension.</article-title>
            <source>Clin Ther</source>
            <year>1986</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-62</page-range>
            <pub-id pub-id-type="pmid">3545477</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
